Digital markers detect changes in neurocognitive performance in those with vs without hearing loss скачать в хорошем качестве

Digital markers detect changes in neurocognitive performance in those with vs without hearing loss

M. Florencia Iulita, PhD, Altoida, Inc., shares the results of a pilot study investigating the performance of a digital biomarker platform in characterizing the neurocognitive profiles of individuals with/without hearing loss. The study looked at the cognitive profiles of three groups: cognitively normal (CN) with hearing loss, CN without hearing loss, and mild cognitive impairment (MCI) with hearing loss. The Altoida digital neuro-signature (DNS) assessment was conducted on a smart device, where the individual had to perform speech and motor tasks and augmented reality exercises reflective of activities of daily living. The study found that individuals with MCI and hearing loss had the lowest Altoida DNS scores, indicating lower cognitive performance. Those who were CN with hearing loss performed similarly to those with MCI and hearing loss, but significantly differently compared to those who were CN without hearing loss. These data demonstrate the presence of distinct cognitive profiles in those with and without hearing loss, and that these differences can be captured using digital biomarker signatures. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.